Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

$80m Windfall Will Push 7 ADC Drug Candidates Into Clinic Within Two Years

This article was originally published in Scrip

Executive Summary

By generating $80m through its latest equity placement, oncology drug development company ADC Therapeutics (ADCT) says it is now well-funded to advance its portfolio of linked tumor-targeted antibody drug conjugates (ADCs) and plans to have seven drug candidates in human clinical trials by-mid 2017, two of which are partnered with AstraZeneca PLC's biologic's division MedImmune LLC.

Advertisement

Related Content

ADC Therapeutics Raises $105m To Reach Pivotal Studies

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC029663

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel